![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
1. Cyt 387
2. Cyt-387
3. Cyt387
4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1. Cyt387
2. 1056634-68-4
3. Cyt-387
4. Cyt 387
5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide
6. Cyt 11387
7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
8. Gs-0387
9. Momelotinib (cyt387)
10. Cyt-11387
11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
14. 6o01gms00p
15. Chembl1078178
16. Cyt-0387
17. Cyt11387
18. Mfcd16038899
19. Lm-1149
20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide
21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide
22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-
23. Momelotinib [usan]
24. Momelotinib [usan:inn]
25. Momelotinibum
26. Unii-6o01gms00p
27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
28. C87
29. Momelotinib [inn]
30. Momelotinib (usan/inn)
31. Momelotinib [who-dd]
32. Mls006011154
33. Gtpl7791
34. Schembl2237234
35. Chebi:91407
36. Ex-a260
37. Dtxsid801026049
38. Hms3244k19
39. Hms3244k20
40. Hms3244l19
41. Hms3295i01
42. Hms3655d12
43. Hms3744c15
44. Bcp02328
45. Cyt387, Cyt11387
46. Cyt387,cyt 11387
47. Momelotinib (cyt387,cyt-387)
48. Bdbm50311017
49. Nsc767598
50. Nsc800800
51. S2219
52. Zinc43199890
53. Akos015904624
54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide
55. Bcp9000570
56. Ccg-264946
57. Cs-0053
58. Db11763
59. Nsc-767598
60. Nsc-800800
61. Sb14602
62. Ncgc00244257-01
63. Ncgc00244257-08
64. Ac-23162
65. As-19389
66. Hy-10961
67. Smr004702928
68. Sy060668
69. Ft-0755949
70. Sw219679-1
71. D10315
72. A857769
73. Q252602
74. J-001468
75. J-523159
76. Brd-k87737963-001-01-1
77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide
78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide
80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387
83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
Molecular Weight | 414.5 g/mol |
---|---|
Molecular Formula | C23H22N6O2 |
XLogP3 | 2.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 6 |
Exact Mass | 414.18042397 g/mol |
Monoisotopic Mass | 414.18042397 g/mol |
Topological Polar Surface Area | 103 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 615 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of myelofibrosis
Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)